PMID: 9167756Jun 1, 1997Paper

A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma

American Journal of Clinical Oncology
I A MalikM Sabih

Abstract

Hepatocellular carcinoma (HCC) is a common tumor in the developing countries. Most patients present with relatively advanced disease and have a poor survival. Due to lack of any effective therapy, there is an urgent need to investigate new drugs. We conducted a prospective trial to evaluate the efficacy and tolerability of ifosfamide (IFEX) in patients with histologically proved, inoperable, localized HCC. Eligibility criteria included World Health Organization (WHO) performance status (PS) of 0-2, bilirubin < or = 3.0 mg/dl, albumin > or = 2.5 g/dl, creatinine < or = 2.0 mg/dl, correctable coagulation profile, adequate bone marrow function, and no prior therapy. Hepatic arterial infusion of IFEX (6 g/m2) was given continuously over 96 hours. Mesna was given intravenously, in same doses, throughout IFEX infusion and for 12 hours afterwards. Nineteen patients were enrolled in the trial. Mean age was 51.1 years and all were men. Most of the patients had PS 1. The majority had viral hepatitis and cirrhosis. Eleven had raised serum alpha fetoprotein (AFP) levels. Thirteen patients had multiple lesions involving both lobes of the liver. Mean size of ultrasonographically evident largest lesion was 11.0 cm. Three patients are inevalua...Continue Reading

References

May 1, 1992·Journal of Hepatology·M Colombo
Sep 1, 1991·HPB Surgery : a World Journal of Hepatic, Pancreatic and Biliary Surgery·J R NovellK E Hobbs
Mar 1, 1988·Annals of Internal Medicine·A M Di BisceglieM T Lotze
Jul 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T KanematsuK Sugimachi
Nov 1, 1988·European Journal of Cancer & Clinical Oncology·S ThongprasertB Sivasomboon
Jan 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K OkudaK Ohnishi
Jan 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E R DicksonR H Wiesner
Jan 1, 1981·Cancer·A B MillerA Winkler
Mar 1, 1994·Annals of Surgery·D G FarmerR W Busuttil
Jun 19, 1993·International Journal of Cancer. Journal International Du Cancer·D M ParkinJ Ferlay

❮ Previous
Next ❯

Citations

Mar 10, 2016·Gastroenterology Research and Practice·Abu Bakar Hafeez BhattiNajmul Hassan Shah
Feb 24, 2001·Clinics in Liver Disease·A Aguayo, Y Z Patt
Jun 2, 2001·Clinics in Liver Disease·A Aguayo, Y Z Patt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.